ClinicalTrials.gg
Enrolling by invitationNCT05097365Updated May 2, 2024

Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity

An interventional study of Vitamin B12 + folic acid supplementation and Placebo supplementation in Overweight and Obesity and Lupus Erythematosus, sponsored by University of Sao Paulo. Enrolling by invitation at 1 site in Brazil. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-05-02.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Obesity by University of Sao Paulo — 5 open to participants now, 11 under way, none of them phase 3. Obesity · University of Sao Paulo.

Planned enrollment
12th of 35
51 · median 40
Started
2022
with 4 others
No phase
30 of 42
5 open now
Primary completion
2022-07
later than 0 of 10 live
Registered
28th of 42
by date

Among the 42 studies in Obesity by University of Sao Paulo, this one is the 12th largest by planned enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2022, is one of 30 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 28th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 42 studies in Obesity by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Obesity by University of Sao Paulo, or all of them as a file.
02

Study summary

Dietary supplementation with methyl donors has been demonstrated to increase DNA methylation in leucocytes whereas a limited dietary intake of methyl donors was associated with DNA hypomethylation. Considering SLE disease, previously study showed that high doses of vitamin B6 and folate were associated with less severe SLE. Furthermore, some evidences reported a relatively high incidence of decreased serum B12 levels in rheumatic patients. This led to the suggestion that diets rich in methyl group donors could have beneficial effects on SLE.

03

Conditions studied

  • Overweight and Obesity
  • Lupus Erythematosus

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 51 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SLE diagnosis
  • Female
  • In pre-menopausal period
  • Aged between 18 to 45 years
  • Patients that meet the classification criteria according to Systemic Lupus International Collaborating Clinics classification criteria (SLICC)
  • Patients with SLEDAI score ≤ 4 on Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
  • Under prednisone treatment at a dosage \<10 mg/day
  • Under treatment with chloroquine at a stable dose
  • > 18,5 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Current infection
  • Diabetes
  • Arterial hypertension
  • Smokers
  • Pregnancy
  • Anticoagulants use
  • Methotrexate use
  • Other diseases
  • Current vitamin B12 or/and folic acid supplementation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    Supplemented Normal Weight Group

    Patients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive supplementation.

    Dietary Supplement: Vitamin B12 + folic acid supplementation

  • Experimental
    Supplemented Excess Body Weight Group

    Patients with excess body weight (BMI \> 25 kg/m²) that will receive supplementation.

    Dietary Supplement: Vitamin B12 + folic acid supplementation

  • Placebo comparator
    Control Normal Weight Group

    Patients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive placebo.

    Dietary Supplement: Placebo supplementation

  • Placebo comparator
    Control Excess Body Weight Group

    Patients with excess body weight (BMI \> 25 kg/m²) that will receive placebo.

    Dietary Supplement: Placebo supplementation

Interventions

  • Dietary supplementVitamin B12 + folic acid supplementation

    A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.

  • Dietary supplementPlacebo supplementation

    A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.

07

What researchers measure

Primary outcomes

  1. Change from baseline on DNA methylation profile at 12 weeks

    Percentage of DNA methylation level

    Time frame: Baseline and 12 weeks

  2. Change from baseline on weight at 12 weeks

    Weight in kilograms

    Time frame: Baseline and 12 weeks

  3. Change from baseline on serum vitamin B12 concentrations at 12 weeks

    Serum vitamin B12 concentrations in pg/mL

    Time frame: Baseline and 12 weeks

  4. Change from baseline on serum folic acid concentrations at 12 weeks

    Serum folic acid concentrations in ng/mL

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Age of onset

    Units of Measure: years

    Time frame: Baseline

  2. Duration of disease since diagnosis

    Units of Measure: years

    Time frame: Baseline

  3. Change from baseline on miR-146 expression at 12 weeks

    Relative miR-146 expression

    Time frame: Baseline and 12 weeks

  4. Change from baseline on miR-181 expression at 12 weeks

    Relative miR-181 expression

    Time frame: Baseline and 12 weeks

  5. Change from baseline on miR-21 expression at 12 weeks

    Relative miR-21 expression

    Time frame: Baseline and 12 weeks

  6. Change from baseline on miR-126 expression at 12 weeks

    Relative miR-126 expression

    Time frame: Baseline and 12 weeks

  7. Change from baseline on TNF-a gene expression at 12 weeks

    Relative gene expression of TNF-a

    Time frame: Baseline and 12 weeks

  8. Change from baseline on LEP gene expression at 12 weeks

    Relative gene expression of LEP

    Time frame: Baseline and 12 weeks

  9. Change from baseline on ADIPOQ gene expression at 12 weeks

    Relative gene expression of ADIPOQ

    Time frame: Baseline and 12 weeks

  10. Change from baseline on MTHFR gene expression at 12 weeks

    Relative gene expression of MTHFR

    Time frame: Baseline and 12 weeks

  11. Change from baseline on STAT3 gene expression at 12 weeks

    Relative gene expression of STAT3

    Time frame: Baseline and 12 weeks

  12. Change from baseline on IL-6 gene expression at 12 weeks

    Relative gene expression of IL-6

    Time frame: Baseline and 12 weeks

  13. Change from baseline on DNMT1 gene expression at 12 weeks

    Relative gene expression of DNMT1

    Time frame: Baseline and 12 weeks

  14. Change from baseline on serum leptin concentrations at 12 weeks

    Serum leptin concentration in ng/mL

    Time frame: Baseline and 12 weeks

  15. Change from baseline on serum IL-6 concentrations at 12 weeks

    Serum IL-6 concentration in ng/mL

    Time frame: Baseline and 12 weeks

  16. Change from baseline on serum IL-17 concentrations at 12 weeks

    Serum IL-17 concentration in ng/mL

    Time frame: Baseline and 12 weeks

  17. Change from baseline on serum IL-2 concentrations at 12 weeks

    Serum IL-2 concentration in ng/mL

    Time frame: Baseline and 12 weeks

  18. Change from baseline on serum TNF-a concentrations at 12 weeks

    Serum TNF-a concentration in ng/mL

    Time frame: Baseline and 12 weeks

  19. Change from baseline on serum C-reactive protein concentrations at 12 weeks

    Serum C-reactive protein concentration in ng/mL

    Time frame: Baseline and 12 weeks

  20. Change from baseline on serum adipokines concentrations at 12 weeks

    Serum adipokines concentration in ng/mL

    Time frame: Baseline and 12 weeks

  21. Change from baseline on serum triglycerides concentrations at 12 weeks

    Serum triglycerides concentration in mg/dL

    Time frame: Baseline and 12 weeks

  22. Change from baseline on serum cholesterol concentrations at 12 weeks

    Serum cholesterol concentrations in mg/dL

    Time frame: Baseline and 12 weeks

  23. Change from baseline on serum glucose concentrations at 12 weeks

    Serum glucose concentrations in mg/dL

    Time frame: Baseline and 12 weeks

  24. Change from baseline on dietary intake at 12 weeks

    Dietary intake in g and percentage

    Time frame: Baseline and 12 weeks

  25. Change from baseline on abdominal circumference at 12 weeks

    Abdominal circumference in centimeters

    Time frame: Baseline and 12 weeks

  26. Change from baseline on fat mass at 12 weeks

    Fat mass in kilograms

    Time frame: Baseline and 12 weeks

  27. Change from baseline on fat free mass at 12 weeks

    Fat free mass in kilograms

    Time frame: Baseline and 12 weeks

  28. Change from baseline on body mass index at 12 weeks

    Body mass index in kilograms/meters\^2

    Time frame: Baseline and 12 weeks

  29. Change from baseline on height at 12 weeks

    Height in meters

    Time frame: Baseline and 12 weeks

08

Study locations

1 site
  • Univsersity of Sao Paulo
    Sao Paulo, 05508-030, Brazil
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jul 2022, 6 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 6 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2021
First posted
Oct 28, 2021
StartActual
Jan 1, 2022
Primary completionActual
Jul 31, 2022
CompletionEst.
Dec 31, 2026
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05097365
Responsible party
Bruno Gualano (Professor, University of Sao Paulo) — Principal investigator
First posted
Oct 28, 2021
Start date
Jan 1, 2022
Primary completion
Jul 31, 2022
Completion
Dec 31, 2026 (estimated)
Last update
May 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion